Our team seeks to shed light on how cells become cancerous. It particularly focuses on the disconnect between the transcriptome and the proteome. Much of this disconnect occurs at the RNA processing level. Here we explore how dysregulated RNA drives and impacts on cancer. Indeed, alterations in RNA processing can literally change the surface of the cell, imbuing it with the capacity to crawl, traverse membrane barriers and even produce extracellular vesicles that may also play roles in metastases. Go here for more details of the different projects.
Further, we have leveraged our novel findings in RNA biochemistry in the clinic, leading three pan-Canadian clinical trials. We use multiple strategies to dissect and target these dysregulated pathways including cell and molecular biology, RNA biochemistry, high-resolution structural studies and state-of-the-art drug screening modalities.
Our work has led to clinical trials. Go here to read more
The activity of the eukaryotic translation initiation factor eIF4E is modulated through conformational response to its ligands. We combine cell biology, RNA biology and structural biology to provide fundamental insights into RNA processing and its dysregulation in cancer. We use eIF4E as a model protein for our studies.